NPM1-mutated AML when these mutations are absent has a median OS of 39 months; in contrast, this figure decreases to 9.9 months when these kinase-signaling mutations are present in parallel with the NPM1 mutation [78,79]. This evidence concerns the gene NPM1 and acute myeloid leukemia.